ANVS

Annovis Bio Inc · NYSE

Sector Health Technology
Industry Pharmaceuticals: Major
Website annovisbio.com
Employees(FY) 5
ISIN US03615A1088

Performance

-21.4%

-34.58%

-49.42%

-17.7%

-76.63%

YTD

-59.35%

Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Advanced Technical Analysis

Technical Analysis of ANVS 2024-12-20

The stock indicators reflect a bearish sentiment, with the Moving Average Score at 10, Oscillators Score at 36, and a Technical Score of 23, indicating overall weakness in price momentum and suggesting caution for potential investors. The low scores across all categories highlight a lack of bullish signals in the current market environment.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ANVS

Stock Rank

Recent News & Updates

2024-12-04 19:30
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace(Globenewswire)
2024-12-04 01:21
Annovis CEO Discusses Breakthrough Drug for Neurodegenerative Diseases on Today's Marketplace(Prnewswire)
2024-11-24 19:00
Annovis to Host Year-End Investor Webcast on December 11, 2024(Globenewswire)
2024-11-11 19:00
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)(Globenewswire)
2024-11-10 19:00
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update(Globenewswire)
2024-11-06 19:00
Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist(Globenewswire)
2024-10-30 20:00
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio(Globenewswire)
2024-10-21 20:00
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024(Globenewswire)
2024-10-16 22:52
Annovis Bio Shows Promise on FDA Clearance for Alzheimer's Drug(Yahoo Finance)
2024-10-14 20:00
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs(Globenewswire)
2024-10-02 20:30
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More(Prnewswire)
2024-10-02 20:30
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases(Globenewswire)
2024-10-01 20:30
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations(Globenewswire)
2024-09-29 20:00
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra(Globenewswire)
2024-09-04 20:00
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-14 19:00
Annovis Bio Reports Second Quarter Financial Results and Provides Business Update(Globenewswire)
2024-08-05 21:00
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities(Globenewswire)
2024-08-05 20:30
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033(Globenewswire)
2024-08-05 20:00
Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist(Globenewswire)
2024-08-04 20:00
IBN Announces Latest Episode of The Bell2Bell Podcast Featuring Annovis Bio CEO Dr. Maria Maccecchini, Live from AAIC 2024(Globenewswire)
2024-07-23 20:00
Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap(Globenewswire)
2024-07-15 20:00
Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap(Globenewswire)
2024-07-08 20:00
Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team(Globenewswire)
2024-07-03 00:53
Annovis stock swells after Phase III Parkinsons subgroup success(Yahoo Finance)
2024-07-03 00:21
Annovis Bio shares dip on phase III Parkinson's trial data(Yahoo Finance)
2024-07-02 21:10
Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study(Zacks)
2024-07-02 04:45
Why Did Annovis Bio (ANVS) Stock Close Up 80% Today?(Investorplace)
2024-07-01 20:00
Annovis Bio Announces New Data from Phase III Parkinson's Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap(Globenewswire)
2024-06-26 20:00
Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap(Globenewswire)
2024-06-25 20:00
Annovis Bio Files Patent for New Composition of Matter for Buntanetap(Globenewswire)

Page 1 of 6

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.